X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs
https://www.globenewswire.com//news-release/2024/01/08/2805043/0/en/Novartis-Scemblix-shows-superior-major-molecular-response-MMR-rates-vs-standard-of-care-TKIs-in-Phase-III-trial-for-newly-diagnosed-patients-with-chronic-myeloid-leukemia.html
https://www.globenewswire.com/news-release/2023/11/20/2782908/0/en/Novartis-showcases-significant-data-updates-from-Kisqali-iptacopan-and-Scemblix-at-SABCS-and-ASH.html
https://www.ema.europa.eu/en/documents/overview/scemblix-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/novartiss-scemblix-asciminib-receives-approval-in-europe-37572.pdf
https://www.newswire.ca/news-releases/scemblix-tm-a-first-in-class-cml-treatment-with-new-mechanism-of-action-approved-in-canada-814932621.html
https://www.pharmatimes.com/news/novartis_receives_vital_licence_for_scemblix_1450124
https://www.pharmatimes.com/news/access_to_novartis_treatment_for_myeloid_leukaemia_patients_1386783
https://endpts.com/two-decades-after-gleevec-approval-novartis-scores-new-cml-ok-for-wild-card-stamp-inhibitor/
https://www.novartis.com/news/media-releases/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia
https://www.fiercebiotech.com/biotech/ash-novartis-3rd-gen-kinase-inhibitor-tops-pfizer-s-bosulif-head-to-head-leukemia-trial
https://www.clinicaltrialsarena.com/news/novartis-asciminib-phaseiii-data/
https://www.fiercebiotech.com/biotech/novartis-asciminib-bests-pfizer-s-bosulif-phase-3-leukemia-trial
https://endpts.com/novartis-halts-phii-cml-study-for-next-gen-allosteric-drug-due-for-a-pivotal-readout-later-this-year/
https://www.prnewswire.com/news-releases/i-mab-biopharma-and-abl-bio-announce-global-collaboration-on-innovative-bispecific-antibodies-300687118.html
Market Place
Share 
